How does MKM compare to Hunan Aslsen Technology on documentation quality?

The specifics, since they change the answer: MKM · Hunan Aslsen Technology.

I am trying to choose between two options that are usually discussed as though only one exists.

I am not optimising for price, but I am not indifferent to it either.

So which one, and on what grounds?

The short version: same compound, same laboratory, same method, ideally same week — otherwise you are comparing laboratories rather than suppliers.

Content is the more discriminating measurement than purity for supplier comparison, because purity clusters tightly among competent suppliers and content does not.

Cost per milligram, adjusted honestly

Cost per milligram of actual peptide is the honest price comparison, which means dividing by measured content rather than by label claim.

Price per milligram of measured peptide, not per milligram of label claim.

The part that matters: a single member running three suppliers on one method is worth more than thirty members running one supplier each.

To compare properly: order the same compound at the same nominal strength from each supplier, submit all samples to the same laboratory in the same submission if possible, and ask for the same test set on each.

The underlying point is that publish the method with the result. A comparison without the laboratory named and the submission dates given is not reproducible by anyone.

Comparisons drawn from different laboratories at different times are weaker evidence than most people treat them as.

Use a fixed documentation checklist rather than an impression.

The relevant point is that two competent laboratories disagree by half a per cent on identical material, which is larger than most of the differences people argue about.

Lead time and lane behaviour are supplier properties too and are easier to compare than analytical ones, because they need no laboratory at all.

Sample size matters. One order each is an anecdote about six vials; three orders each over a year is the beginning of a comparison.

Content assay results across the published datasets vary considerably more between suppliers than purity does, which makes content the more discriminating axis.

Nothing here is medical advice, and research-use compounds are not approved for human use.

One laboratory, one method, one submission. Otherwise it is not a comparison.

Start by asking what you are optimising for, because cost per milligram, documentation depth and lead time do not have a common winner.

Submitting to different laboratories introduces a method difference that commonly exceeds the supplier difference. Gradient slope alone can move a reported purity figure by a per cent in either direction.

The ratings on this site are a community opinion average on a ten-point scale and are not reconciled with any other community's figures.

Name the laboratory and the dates or the comparison cannot be reproduced.

Answer first: comparing suppliers is only meaningful if the comparison holds the laboratory, the method and the compound constant, and most published comparisons hold none of them.

Compare documentation on a fixed checklist rather than by impression: lot specificity, method section, chromatogram availability, quantified content, water and counter-ion figures, and whether the code is on the vial.

Inter-laboratory spread on identical peptide material is routinely half a per cent to a per cent by RP-HPLC, which is the noise floor for any cross-laboratory comparison.

Compare content, not purity. Purity clusters and content does not.